| Categories | p | HR | 95%-CI |
---|---|---|---|---|
Disease-free interval | ||||
 Bcl-2 expression | Bcl-2+ versus Bcl-2– | 0.017 | 0.09 | 0.01–0.64 |
 Pathologic tumor size | pT ≥ 20 mm versus < 20 mm | 0.047 | 2.23 | 1.02–4.91 |
 Tumor-associated inflammation | Absence to mild versus moderate to severe | 0.033 | 0.40 | 0.18–0.92 |
Overall survival | ||||
 Bcl-2 expression | Bcl-2+ versus Bcl-2– | 0.008 | 0.28 | 0.11–0.72 |
 Pathologic tumor size | pT ≥ 20 mm versus < 20 mm | 0.014 | 2.07 | 1.16–3.70 |
 Tumor-associated inflammation | Absence to mild versus moderate to severe | 0.012 | 0.44 | 0.23–0.84 |
Cancer-specific survival | ||||
 Bcl-2 expression | Bcl-2+ versus Bcl-2– | 0.031 | 0.31 | 0.11–0.89 |
 Pathologic tumor size | pT ≥ 20 mm versus < 20 mm | 0.026 | 2.10 | 1.09–4.02 |
 Tumor-associated inflammation | Absence to mild versus moderate to severe | 0.022 | 0.43 | 0.21–0.88 |